Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I, Arteriocyte Magellan MAR01 Therapy - Compartment Syndrome and Battlefield Trauma Study Protocol

NCT01837264 is registered in ClinicalTrials.gov with Arteriocyte, Inc. as lead sponsor.

NCT NCT01837264
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01837264 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I, Arteriocyte Magellan MAR01 Therapy - Compartment Syndrome and Battlefield Trauma Study Protocol
Lead sponsor
Arteriocyte, Inc.
Phase
Phase 1
Overall status
Completed
Start date
January 31, 2013
Completion date
January 31, 2017
Enrollment
5 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

compartment syndrome